Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 7c

Go back to Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 7c

Syros Pharmaceuticals (SYRS) PT Lowered to $26 at Oppenheimer

August 7, 2018 10:34 AM EDT

Oppenheimer lowered its price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $26.00 (from $28.00) while maintaining a Outperform rating.

... More